Axogen Chief R&D Officer Scopelianos resigns; transition consulting through Dec 2024

Axogen, Inc.

Angelo Scopelianos resigns as Chief R&D Officer effective no later than March 31, 2024.
He will consult up to 10 hrs/wk from Apr 1 to Dec 31, 2024 for $9,079.16/month plus a $75,000 one-time payment if through Oct 1.
Scopelianos receives his 2023 bonus of $228,385.26 on March 15, 2024.
Unvested stock options continue vesting through consulting period; RSUs and unvested PSUs cease at separation.
Product development duties assumed by VP Stacy Arnold, who reports directly to CEO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Angelo Scopelianos

Chief Research and Development Officer

AXGN · Axogen, Inc.

Effective: 2024-03-31
Filed: March 8, 2024, 6:59 PM ET

Angelo Scopelianos notified Axogen, Inc. (the “Company”) of his intention to resign as the Company’s Chief Research and Development Officer no later than March 31, 2024 (the “Separation Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Angelo Scopelianos resigned as Chief Research and Development Officer at Axogen, Inc..

Action: resigned
Role: Chief Research and Development Officer

Exact text from the filing

Angelo Scopelianos notified Axogen, Inc. (the “Company”) of his intention to resign as the Company’s Chief Research and Development Officer no later than March 31, 2024 (the “Separation Date”).

View on SEC.gov

Axogen, Inc. filing history →

Source: SEC EDGAR

accession 0000805928-24-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.